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Abstract
Background: Bromodomain is an evolutionally conserved domain that is found in proteins strongly implicated in signal-
dependent transcriptional regulation. Genetic alterations of bromodomain genes contributed to the development of many
human cancers and other disorders. BRD7 is a recently identified bromodomain gene. It plays a critical role in cellular growth,
cell cycle progression, and signal-dependent gene expression. Previous studies showed that BRD7 gene exhibited much higher-
level of mRNA expression in normal nasopharyngeal epithelia than in nasopharyngeal carcinoma (NPC) biopsies and cell lines.
However, little is known about its transcriptional regulation. In this study, we explored the transcriptional regulation of BRD7
gene.
Method: Potential binding sites of transcription factors within the promoter region of BRD7 gene were predicted with
MatInspector Professional http://genomatix.de/cgi-bin/matinspector_prof/mat_fam.pl. Mutation construct methods and
luciferase assays were performed to define the minimal promoter of BRD7 gene. RT-PCR and western blot assays were used
to detect the endogenous expression of transcription factor Sp1, c-Myc and E2F6 in all cell lines used in this study.
Electrophoretic mobility shift assays (EMSA) and Chromatin immunoprecipitation (ChIP) were used to detect the direct
transcription factors that are responsible for the promoter activity of BRD7 gene. DNA vector-based siRNA technology and
cell transfection methods were employed to establish clone pools that stably expresses SiRNA against c-Myc expression in
nasopharyngeal carcinoma 5-8F cells. Real-time PCR was used to detect mRNA expression of BRD7 gene in 5-8F/Si-c-Myc cells.
Results: We defined the minimal promoter of BRD7 gene in a 55-bp region (from -266 to -212bp), and identified that its
promoter activity is inversely related to c-Myc expression. Sp1 binds to the Sp1/Myc-Max overlapping site of BRD7 minimal
promoter, and slightly positively regulate its promoter activity. c-Myc binds to this Sp1/Myc-Max overlapping site as well, and
negatively regulates the promoter activity and endogenous mRNA expression of BRD7 gene. Knock-down of c-Myc increases
the promoter activity and mRNA level of BRD7 gene. The luciferase activity of the mutated promoter constructs showed that
Sp1/Myc-Max overlapping site is a positive regulation element of BRD7 promoter.
Conclusion: These studies provide for the first time the evidence that c-Myc is indeed a negative regulator of BRD7 gene.
These findings will help to further understand and uncover the bio-functions of BRD7 gene involved in the pathogenesis of NPC.
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Background
Bromodomain consists of a motif of 59–63 amino acids
[1]. It is a protein-protein interaction domain and has a
specific binding affinity for acetylated lysines on N-termi-
nal tails of histones [2]. Several studies demonstrated that
bromodomain is characteristic of proteins that regulate
signal-dependent, but not basal, transcription during
active proliferation through modulating chromatin
remodeling or acetylation of histones, therefore facilitat-
ing accession of transcription factors to chromatin [3,4].
Accummulating evidence showed that the genetic altera-
tions of bromodomain genes contributed to the develop-
ment of many human cancers and other disorders [5,6].
BRD7 is a bromodomain-containing gene identified from
Nasopharyngeal carcinoma (NPC) cells by cDNA Repre-
sentational Difference Analysis [7]. Due to the sequence
similarity with other bromodomain containing protein, it
was suggested that BRD7 may be as components of chro-
matin remodeling complexes and possess histone acetyl-
transferase activity [8]. Together with E1B-AP5, BRD7
functions as an inhibitor of basic transcription in several
viral and cellular promoters in the nucleus [9]. STAAL et
al. demonstrated that BRD7 protein (celtix-1) interacted
with interferon regulatory factor 2 in the nucleus and
associated with transcriptionally active chromatin in situ
[10]. BP75, the most homologous gene of BRD7, directly
interacts with Dvl-1, enhances TCF-dependent gene
expression induced by Dvl-1, and induces the nuclear
translocation and formation of vesicular structures of
beta-catenin with Dvl-1 in a synergistic manner [11], indi-
cating that BRD7 may play an important role in Wnt sig-
naling. An alternative critical role of BRD7 gene arose
from evidence that BRD7 gene exhibited much higher-
level of mRNA expression in normal nasopharyngeal epi-
thelia than in NPC biopsies and cell lines [12]. Over-
expression of BRD7 gene in NPC cells was effective to
inhibit cell growth and cell cycle progression from G1 to
S phase [12-14]. But little is known about its transcrip-
tional regulation. Our previous studies located the pro-
moter of BRD7 gene in a 125 bp region (-293→-168 bp)
[15]. In this report, we defined the minimal promoter of
BRD7 gene in a 55-bp region, and explored the role of c-
Myc in suppressive regulating of BRD7 expression in NPC
cells. These findings will help to further understand and
uncover the functions of BRD7 gene in the pathogenesis
of NPC, and also provide a molecular model for studying
the transcriptional regulation of other bromodomain
family genes.
Results
Identification of BRD7 minimal promoter
In order to define the minimal promoter of BRD7 gene,
six deletion constructs were generated from full-length
promoter construct pGL3-404/+46 (Fig. 1). As shown in
Fig. 2A, pGL3-404/+46 expresses strong luciferase activity
(approximately 5.5 × 107 luc/μg protein) in both COS7
and 5-8F cells. Two of the constructs, pGL3-311/+46 and
pGL3-404/+46/(del-152/+3), show luciferase activity
equally strong with the full length construct, whereas
pGL3-168/+46 and pGL3-404/+46/(del-293/-168) dis-
play substantially lower luciferase activity (approximately
5.5 × 103 luc/μg protein). Surprisingly, the luciferase
activities of pGL3-266/+46 and pGL3-266/-212, are as
strong as that of pGL3-404/+46 in COS7 cells, but have
almost no activity in 5-8F cells (Fig. 2A).
Indeed, the selective promoter activity of pGL3-266/-212
in COS7 and 5-8F cells was confirmed by direct GFP fluo-
rescence assay. As shown in Fig. 2B, pGL3-404/+46/GFP
exhibits strong GFP fluorescence both in 5-8F and COS7
cells, whereas pGL3-266/-212/GFP displays fluorescence
only in COS7 cells, but shows almost no fluorescence in
5-8F cells.
BRD7 minimal promoter activity is inversely related to c-
Myc expression
We next detected the activity of BRD7 minimal promoter
in other cell types by using the luciferase assay. As shown
in Fig. 3A, the luciferase activity of pGL3-266/-212 in
COS7 cells is 99.75% of the luciferase activity of pGL3-
404/+46 in COS7 cells, but only 30.56% and 33.80% of
the luciferase activity of pGL3-404/+46 in HEK293 and
U251 cells respectively. No luciferase activity of pGL3-
266/-212 was found in HNE1, CNE1, 6-10B, 5-8F, MCF-7
and SW480 cells. Direct GFP fluorescence assay showed
similar results (data not shown). These results indicate
that the 55-bp promoter fragment -266/-212 of BRD7
gene selectively functions in some cell types.
To identify the upstream regulatory factor(s) of BRD7
minimal promoter, which might account for the suppres-
sive regulation of BRD7 promoter activity in the above
mentioned cell lines, we analyzed sequence -266/-212 of
BRD7 gene by using MatInspector Professional program.
As shown in Fig. 3B, three critical putative binding sites
including the binding site for MYC-MAX (-260/-246), an
E2F6 binding site (-246/-229), and a Sp1/Myc-Max over-
lapping site (-223/-198) were found. We, therefore, exam-
ined the endogenous expression of these transcription
factors in all cell lines used in this study. As shown in Fig.
3D, Sp1 is ubiquitously expressed in all cell lines whereas
E2F6 is expressed in all analyzed cells except COS7 cells.
In RT-PCR assay, two different bands were amplified in
COS7 cells by using the same primers to detect E2F6
expression in other eight cell lines (Fig. 3C). c-Myc was
expressed strongly in the cell lines including HNE1,
CNE1, 6-10B, 5-8F, MCF-7 and SW480, in which pro-
moter -266/-212 showed almost no activity. Very weakly
expressed c-Myc was detected in COS7, HEK293 and
U251 cells, in which promoter -266/-212 was active (Fig.BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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3A, C, and 3D). These results indicate that the activity of
BRD7 minimal promoter is inversely related to c-Myc
expression, suggesting that c-Myc may play a critical role
in regulating of BRD7 minimal promoter.
Transcription factor Sp1 and c-Myc specifically binds to 
BDR7 minimal promoter
To identify the direct transcription factors that are respon-
sible for the promoter activity of BRD7 gene, EMSA and
supershift assays were performed. As shown in the right
panel of Fig. 4A, a strong and a weak DNA-protein com-
plex was formed by using the radiolabeled -223/-198 frag-
ment as a probe. The complex formation was fully
suppressed by the addition of a 100-fold molar excess of
cold wild type -223/-198 fragment (self inhibition), but
not by 100-fold molar excess of cold mutated -223/-198
fragment as competitor. Moreover, this complex can be
shifted with either anti-Sp1 or anti-c-Myc, but not with
Schematic illustration of deletion constructs of BRD7 promoter Figure 1
Schematic illustration of deletion constructs of BRD7 promoter.BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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irrelevant HA antibody. These results indicate that the
Sp1/Myc-Max binding site at -223 to -198 is specific. Both
Sp1 and c-Myc are able to bind to the overlapping site of
Myc-MAX/Sp1.
The specificity of the E2F6 binding site was analyzed with
a probe coding for an E2F6 binding site spanning from -
243 to -229 bp. Two DNA-protein bands found. They
were totally inhibited by the addition of 100-fold molar
excess of cold wild type oligonucleotide, but not by 100-
fold molar excess of cold mutated oligonucleotide as com-
petitors (Middle panel of Fig. 4A). These complexes can't
be shifted with either anti-E2F6 or anti-HA, indicating
that the E2F6 binding site at -243/-229 of BRD7 promoter
is a functional binding site, but is not an E2F6-specific
site.
Finally, we examined the specificity of MYC-MAX binding
site at -260 to -246 of BRD7 minimal promoter. A strong
and a weak DNA-protein complex were formed with -260/
-246 as a probe, and both were completely abolished by
adding either 100-fold molar excess cold wild type -260/-
246 or the cold mutated -260/-246 as competitors. These
data implied that the protein-DNA complexes formed at -
260 to -246 were nonspecific (Left panel of Fig. 4A).
Identificating of BRD7 minimal promoter (-266/-212) Figure 2
Identificating of BRD7 minimal promoter (-266/-212). (A) Luciferase assay of deletion constructs of BRD7 promoter. 
Luciferase activity in COS7 and 5-8F cells is represented by black and gray histograms, respectively. (B) Detection of GFP fluo-
rescence of modified construct pGL3/-266,-212/EGFP in COS7 and 5-8F cells by direct GFP fluorescence assay. Full-length 
modified promoter construct pGL3/-404,+46/EGFP was used as a positive control. A1, B1: COS7 cells transfected with pGL3/
-404,+46/GFP; A2, B2: COS7 cells transfected with pGL3/-266,-212/GFP; A3, B3: 5-8F cells transfected with pGL3/-404,+46/
GFP; A4, B4: 5-8F cells transfected with pGL3/-266,-212/GFP.BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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To investigate whether transcription factor Sp1, c-Myc or
E2F6 interacts with BRD7 minimal promoter through
their specific binding sites in vivo, we performed ChIP
assay. Because of the high GC content (more than 80%)
in the region from -266 to -212 bp, it is very difficult to
design the primers for amplifying of the sequence span-
ning -266 to -212 bp in ChIP assay. We designed the prim-
ers for amplification the sequence spanning -274 to -162
bp. As shown in the left panel of Fig. 4B, with the DNA
samples immunoprecipitated in 5-8F cells by polyclonal
rabbit antibodies against Sp1 and c-Myc as templates
respectively, a 133 bp DNA fragment of BRD7 promoter
could be amplified by using the indicated BRD7 primers
(upper bands), but none by the primers of unrelated
genomic region of GAPDH gene (lower bands). In con-
trast, no DNA fragment of BRD7 promoter could be
amplified by using DNA samples immunoprecipitated by
anti-E2F6 as a template. A 133 bp DNA fragment of BRD7
promoter and a 229 bp unrelated genomic region of
GAPDH gene were amplified by using the input as tem-
plates. When DNA samples immunoprecipitated with
irrelevant anti-HA (negative control) were used as tem-
plates, no amplification occurred with either BRD7 prim-
ers or GAPDH primers. Moreover, we did ChiP assays
using nuclear protein isolated from 5-8F/Si-c-Myc cells. As
shown in the right panel of Fig. 4B, with the DNA samples
immunoprecipitated in 5-8F/Si-c-Myc cells by Sp1 anti-
bodies as templates, a 133 bp DNA fragment of BRD7 pro-
moter could be amplified, whereas no DNA fragment of
BRD7 promoter could be amplified by using DNA sam-
ples immunoprecipitated in 5-8F/Si-c-Myc cells by anti-c-
Myc as templates. Taking together, we concluded that
transcription factor Sp1 and c-Myc specifically bind to
BRD7 minimal promoter.
BRD7 minimal promoter selectively functions in some cell lines with weak expression of c-Myc Figure 3
BRD7 minimal promoter selectively functions in some cell lines with weak expression of c-Myc. (A) Luciferase 
assay of pGL3/-266,-212 in different cultured cell lines. Luciferase activity of pGL3/-404,+46 and pGL3/-266,-212 is represented 
by black and gray histograms, respectively. (B) Bioinformatics analysis of putative cis-acting elements in BRD7 minimal pro-
moter region -266/-212 by MatInspector program. "+1" represents the A of the initiation translation codon. (C) Detection of 
c-Myc, E2F6 expression in nine analyzed cell lines by RT-PCR. (D) Detection of Sp1, c-Myc and E2F6 expression in nine ana-
lyzed cell lines by western blot assay.BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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The Sp1/Myc-Max overlapping site is specific in BRD7 minimal promoter Figure 4
The Sp1/Myc-Max overlapping site is specific in BRD7 minimal promoter. (A) Top: The sense sequences of oligonu-
cleotides used in electrophoretic mobility-shift assay. Bottom: Identification of specific E2F6 and Sp1/Myc-Max overlapping site 
in BDR7 minimal promoter. Oligonucleotides -260/-246, -243/-229 and -223/-198 containing a putative MYC-MAX, an E2F-6 
binding site and a Sp1/Myc-Max overlapping site were respectively radiolabeled and incubated with 8 μg nuclear extracts of 5-
8F cells in EMSA. For competition assay, 100-molar excess of unlabeled wild type or mutated oligonucleotide -260/-246, -243/-
229 and -223/-198 were added to the reaction mixture, respectively, before the addition of radiolabeled probes. NP represents 
nuclear protein. In the supershift experiments, 2 μg antibody of Sp1 (Upstate Biotechnology), c-Myc (Sigma), E2F6 (Santa Cruz 
Biotechnology) and irrelevant anti-HA (Santa Cruz Biotechnology) was added to the reaction, respectively. (B) Transcription 
factor c-Myc and Sp1 are in vivo associated with BRD7 minimal promoter. Left panel: equivalent amounts of chromatin were 
immunoprecipitated in 5-8F cells by antibodies as indicated or an irrelevant antibody (Anti-HA) as a control. Right panel: equiv-
alent amounts of chromatin were immunoprecipitated in 5-8F/Si-c-Myc cells by antibodies as indicated. PCR was performed 
using the indicated BRD7 primers or GAPDH primers.BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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Role of the transcription factor Sp1 in the regulation of 
BRD7 promoter activity
To determine the role of Sp1 in regulating BRD7 minimal
promoter, different amounts of expressing vector pCMV-
HA/Sp1 were co-transfected with promoter construct
pGL3/-266,-212 into HNE1 and 5-8F cells, respectively.
As shown in Fig. 5A, overexpression of Sp1 slightly
increases the promoter activity of pGL3-266/-212 in both
HNE1 and 5-8F cells. Similar results were observed in
CNE1, 6-10B, MCF-7 and SW480 cells (data not shown).
Is this due to the invalid Sp1 binding site? To further con-
firm the Sp1 binding site at position -223 to -198, two
mutated promoter constructs were created. Construct
Sp1/Myc-Max/SM was generated by site mutation of three
key nucleotides (C/A, G/T, G/A) of Sp1/Myc-Max ele-
ment, whereas Sp1/Myc-Max/DM, was generated by delet-
ing nine nucleotides of Sp1/Myc-Max element (Fig. 5B).
After transfection into 5-8F cells, both Sp1/Myc-Max/SM
and Sp1/Myc-Max/DM exhibited the same low activity as
compared to wild type pGL3/-266,-212. In COS7 cells,
wild type pGL3/-266,-212 showed strong promoter activ-
ity (approximately 5.2 × 107 luc/μg protein), but both
Sp1/Myc-Max/SM and Sp1/Myc-Max/DM displayed sub-
stantially low promoter activity (Fig. 5B). All these data
indicated that the Sp1/Myc-Max element spanning from -
223 to -198 bp is a positive regulatory element. Mutating
three key nucleotides of Sp1/Myc-Max element was suffi-
cient to abolish Sp1 binding to this region and positively
regulating of BRD7 promoter activity.
c-Myc inhibits the promoter activity and endogenous 
mRNA expression of BRD7 gene
To elucidate the effects of c-Myc on regulating of BRD7
minimal promoter, pGL3/-266,-212 and pGL3/-266,-
212/GFP were co-transfected with various amounts of
pCMV-HA/c-Myc into COS7 cells, respectively. As shown
Transcriptional factor Sp1 slightly increases BRD7 promoter activity in NPC HNE1 and 5-8F cells Figure 5
Transcriptional factor Sp1 slightly increases BRD7 promoter activity in NPC HNE1 and 5-8F cells. Mutation of 
Sp1 element decreases the activity of BRD7 minimal promoter in COS7 cells. (A) 0.5 μg pGL3/-266,-212 was cotransfected 
with 0.25 μg SV40 β-galactosidase vector and various indicated amounts of pCMV-HA/Sp1 into HNE1 and 5-8F cells by Lipo-
fectamine 2000 Reagent. Luciferase activity was measured in cell extracts 38 h after transfection. The SV40 β-galactosidase vec-
tor was used for normalizing transfection efficiency. Data are the means ± S.D. of three independent experiments. (B) Top: 
The promoter fragment (sense) sequences to construct wild type and mutant Sp1/Myc-Max binging site reporter constructs of 
BRD7 minimal promoter -266/-212. Bottom: 0.5 μg promoter construct pGL3/-266,-212, Sp1/Myc-Max/SM and Sp1/DM were 
respectively cotransfected with 0.25 μg SV40 β-galactosidase vector into COS7 or 5-8F cells by Lipofectamine 2000 Reagent. 
Luciferase activity was measured in cell extracts 38 h after transfection. The SV40 β-galactosidase vector was used for normal-
izing transfection efficiency. Data are the means ± S.D. of three independent experiments.BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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in Fig. 6A, 1.0 μg of pCMV-HA/c-Myc was sufficient to
completely inhibit the promoter activity of pGL3/-266,-
212. Similarly, no direct GFP fluorescence was found in
cells co-transfected with pGL3/-266,-212/GFP and pCMV-
HA/c-Myc (Fig. 6B), while strong direct GFP fluorescence
was observed in cells co-transfected with pGL3/-266,-212/
GFP and the control construct pCMV-HA (Fig. 6B). More-
over, the suppressive role of c-Myc in regulating of BRD7
mRNA expression was investigated by RT-PCR and real-
time PCR. As shown in Fig. 6C, obvious down-regulating
of BRD7 mRNA expression was achieved by overexpres-
sion of c-Myc in both COS7 and U251 cells as compared
to overexpression of the control vector pCMV-HA. Over-
expression of c-Myc decreased more than 43% of BRD7
mRNA expression in COS7 cells (Fig. 6D). All these data
suggested that transcription factor c-Myc could signifi-
cantly suppress the promoter activity and endogenous
mRNA expression of BRD7 gene.
c-Myc inhibits promoter activity and endogenous mRNA level of BRD7 gene Figure 6
c-Myc inhibits promoter activity and endogenous mRNA level of BRD7 gene. (A) Luciferase assay of 0.5μg pGL3/-
266,-212 in COS7 cells cotransfected with various indicated amounts of pCMV-HA/c-Myc. The SV40 β-galactosidase vector 
was used for normalizing transfection efficiency. Data are the means ± S.D. of three independent experiments. (B) Top: 0.5 μg 
modified reporter construct pGL3/-266,-212/GFP was cotransfected with 2.5 μg pCMV-HA/c-Myc or 2.5 μg pCMV-HA into 
COS7 cells by Lipofectamine 2000 Reagent. 38 h after transfection, the signal of EGFP fluorescence driven by promoter frag-
ment -266/-212 was observed by using an AX-80 analytical microscope system (Olympus, Tokyo, Japan). A1, B1: COS7 cells 
cotransfected with pGL3/-404,+46/GFP and pCMV-HA; A2, B2: COS7 cells cotransfected with pGL3/-266,-212/GFP and 
pCMV-HA-c-Myc. Bottom: After examining the direct GFP fluorescence, the analyzed COS7 cells were subjected to immuno-
blot assay with anti-GFP as the primary antibody to detect the EGFP expression driven by promoter fragment -266/-212 with 
or without overexpression of pCMV-HA-c-Myc. pCMV-HA was used as control. (C) and (D) Examination of BRD7 expression 
in COS7 cells transfected with pCMV-HA/c-Myc by RT-PCR and Real-time PCR, respectively. pCMV-HA was used as a nega-
tive control.BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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Knockdown of endogenous c-Myc increases the promoter 
activity and mRNA expression of BRD7 gene
To further uncover the role of c-Myc in negative regulation
of BRD7 expression, we employed DNA vector-based
siRNA technology, by which small DNA inserts encoding
short hairpin RNA against c-myc expression were cloned
into pRNAT-U6.1 vector, and named as pRNA-U6.1/neo/
c-Myc. pRNA-U6.1/neo empty vector was used as a nega-
tive control. pRNA-U6.1/neo/c-Myc and pRNA-U6.1/neo
were transfected into 5-8F cells to establish clone pool
that stably expressing siRNA against c-Myc expression. As
shown in Fig. 7A, knockdown of c-Myc decreased the pro-
tein expression of c-Myc in 5-8F cells.
To identify the effects of knockdown of endogenous c-
Myc expression on BRD7 promoter activity, the promoter
construct pGL3/-266,-212 was transfected into either 5-
8F/Si-c-Myc or 5-8F/Si-control cells. As shown in Fig. 7B,
BRD7 promoter activity increases ten folds in 5-8F/Si-c-
Myc cells, indicating that knock-down of endogenous c-
Myc increases the promoter activity of BRD7 gene.
We, next, examined the effect of knockdown of c-Myc on
endogenous BRD7 expression. mRNA expression level of
BRD7 gene detected in 5-8F/Si-c-Myc cells was higher
than in 5-8F/Si-control cells (Fig. 7C). The relative BRD7
mRNA level relative to GAPDH mRNA level was 1.8408 in
5-8F/Si-c-Myc cells as compared to 1.2542 in 5-8F/Si-con-
trol cells (Fig. 7D). This indicates that knockdown of c-
Myc expression increased by 46% of the endogenous
mRNA expression of BRD7 gene as compared to the par-
allel negative control.
Discussion and conclusion
Nasopharyngeal carcinoma (NPC) is a head and neck
malignancy with high occurrence in South-East Asia and
Southern China [16,17]. Previous studies show that EB
virus, environmental factors, and genetic susceptibility
play important roles in the pathogenesis of NPC [18,19].
BRD7 is one of the genes identified from Nasopharyngeal
carcinoma (NPC) cells by cDNA Representational Differ-
ence Analysis (cDNA RDA) [7]. It exhibited much higher-
level of mRNA expression in normal nasopharyngeal epi-
thelia than in nasopharyngeal carcinoma (NPC) biopsies
and cell lines [12]. However, little is known about its tran-
scriptional regulation.
In this report, we defined the minimal promoter of BRD7
gene in a 55 bp region, which is the shortest promoter
identified so far in the regulatory region of BRD7 gene.
Surprisingly, we found that this 55 bp region displayed
high promoter activity in COS7, HEK293 and U251 cells,
but exhibited extremely low activity in HNE1, CNE1, 6-
10B, 5-8F, MCF-7 and SW480 cells as compared to the
full-length promoter -404/+46. What causes it? MatIn-
spector analysis revealed a MYC-MAX, an E2F6 and a Sp1/
Myc-Max overlapping site in BRD7 minimal promoter,
suggesting that transcription factor E2F6, c-Myc and Sp1
may be involved in regulating of BRD7 minimal pro-
moter.
Sp1 is a well-investigated factor that regulates transcrip-
tion through specific sequences in G/C-rich promoter
regions and is often critical for transcriptional initiation of
TATA-less promoters [20,21]. BRD7 gene contains a G/C
rich promoter, in which there are several potential Sp1
binding sites and no TATA boxes. EMSA along with ChIP
assays confirmed a specific Sp1/Myc-Max overlapping site
spanning from -223 to -198 bp in BRD7 minimal pro-
moter. Overexpression of Sp1 slightly increased the activ-
ity of BRD7 minimal promoter in NPC HNE1 and 5-8F
cells. Is it because of the invalid Sp1 binding site? To end
this point, two mutated promoter constructs including
Sp1/Myc-Max/SM and Sp1/Myc-Max/DM were generated.
The results showed that the Sp1/Myc-Max overlapping site
in the region from -223 to -198 bp is a positive regulatory
element. Mutating three key nucleotides of Sp1/Myc-Max
element was sufficient to abolish its positive regulation of
BRD7 promoter activity. These data confirmed the posi-
tively regulating role of Sp1/Myc-Max site in BRD7 pro-
moter, on the other hand, inferred the possibility that the
weakly positive role of Sp1 may result from the influence
of some negatively regulating factors.
c-Myc is a basic helix-loop-helix leucine zipper transcrip-
tion factor, and over-expressed in most human cancers
[22]. c-Myc executes its multiple activities mostly through
transcriptional regulation of the target genes by binding to
several hundred genomic loci harboring consensus c-Myc
binding sites, termed E-boxes, resulting in transcriptional
activation of their adjacent genes [23]. Additionally, a
large number of genes such as cell cycle/growth arrest
genes gas1, p15, p21, p27, and gadd34, -45, and -153 are
down-regulated by c-Myc [24-26]. In our study, c-Myc
binds BRD7 minimal promoter, and negatively regulates
the promoter activity and endogenous mRNA expression
of BRD7 gene. Whereas knock-down of c-Myc increases
the promoter activity and mRNA level of BRD7 gene in
NPC 5-8F cells. From these findings, we concluded that c-
Myc is indeed a negative regulator of BRD7 gene.
In conclusion, these studies showed several lines of evi-
dences of BRD7 transcriptional mechanisms: (1) c-Myc
expression is inversely corresponding to BRD7 promoter
activity. (2) Sp1 binds to BRD7 promoter and slightly pos-
itively regulates BRD7 promoter activity. (3) c-Myc binds
to BRD7 promoter and negatively regulates BRD7 pro-
moter activity and mRNA expression. Together these stud-
ies provide a molecular model for c-Myc in suppressive
regulation of BRD7 promoter activity and mRNA expres-BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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sion. These results will help to better understand the role
of BRD7 gene in signal-dependent transcriptional regula-
tion and uncover the bio-functions of BRD7 involved in
the pathogenesis of NPC as well as provide new potential
therapeutic target for cancer therapy from the view of
overexpression of BRD7 and knock-down of c-Myc gene.
Knockdown of endogenous c-Myc increases the promoter activity and mRNA transcription of BRD7 gene Figure 7
Knockdown of endogenous c-Myc increases the promoter activity and mRNA transcription of BRD7 gene. (A) 
Detecting of c-Myc expression level in 5-8F/Si-c-Myc and 5-8F/Si-control cells by immunoblot analysis. The anti-c-Myc was used 
as primary antibody. The expression of α-tubulin was used as an internal control. (B) Luciferase assay of pGL3/-266,-212 pro-
moter activity in 5-8F/Si-c-Myc and 5-8F/Si-control cells. Luciferase activity was measured in cell extracts 38 h after transfec-
tion. The SV40 β-galactosidase vector was used for normalizing transfection efficiency. Data are the means ± S.D. of three 
independent experiments. (C) Detection of BRD7 expression in 5-8F/Si-c-Myc and 5-8F/Si-control cells by RT-PCR. The PCR 
products were analyzed by electrophoresis on a 2%BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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Methods
Cell culture and antibodies
Most of the cell lines used in this study is from the Amer-
ican Type Culture Collection (ATCC) cell bank. COS7
cells (African green monkey kidney fibroblast-like cell line
transfected with vectors requiring expression of SV40 T
antigen. ATCC CRL-1651), HEK293 cells (human embry-
onic kidney cell line transformed with adenovirus 5 DNA,
ATCC CRL-1573), MCF-7 cells (human breast adenocarci-
noma cell line, ATCC HTB-22) and U251 cells (human
glioblastoma cell line, JCRB, IFO50288) were cultured in
Dulbecco modified Eagle medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), 100 U/ml penicillin and 100 μg/ml streptomycin at
37°C, 5% CO2. SW480 cells (human colorectal adenocar-
cinoma cell line, ATCC CCL-228) were cultured in
RPMI1640 medium containing 10% FBS and incubated as
described above. NPC CNE1, 5-8F and 6-10B are human
nasopharyngeal carcinoma cells which provided by the
Cancer Center of Sun Yet-Sen University, (Guangzhou,
China). NPC HNE1 cells were provided by Cancer
Research Institute of Central South University (Hunan,
China). HNE1, CNE1, 6-10B and 5-8F cells were cultured
in RPMI1640 medium containing 10% FBS.
Anti-Sp1 is from Upstate Biotechnology. Anti-c-Myc, GFP
and β-actin were from Sigma. Anti-HA and anti-E2F6 are
from Santa Cruz Biotechnology.
Bioinformatics
Potential binding sites of transcription factors within the
promoter region spanning from -266 to -212 bp of BRD7
gene were performed with MatInspector Professional
http://genomatix.de/cgi-bin/matinspector_prof/
mat_fam.pl.
Construction of Reporter vectors
Ten reporter constructs of BRD7 promoter were created.
Five of them (pGL3-404/+46/(del-293/-168), pGL3-404/
+46/(del-152/+3), pGL3-311/+46, pGL3-266/+46, pGL3-
168/+46) originating from the construct pGL3-404/+46
were amplified by PCR using the primers listed in Table 1.
The protruding ends were digested and phosphorated in
one reaction system with Blunting Kination Ligation kit
(TaKaRa, Japan). The resulted blunt-ended vectors were
self-ligated with T4 ligase, then transformed into
Escherichia coli JM109. The wild type and two mutated
constructs of pGL3-266/-212 were generated by synthesiz-
ing the wild type and mutated fragments of BRD7 pro-
moter sequence (Fig. 5B) spanning from -266 to -212 bp
in TaKaRa, Japan, cutting with enzyme KpnI and NheI,
subcloning into pGL3-enhancer digested with the same
enzymes, then naming as pGL3-266/-212, Myc-Max/Sp1/
SM, Myc-Max/Sp1/DM.
Two other reporter constructs (pGL3-404/+46/GFP,
pGL3-266/-212/GFP) were generated by replacing the
luciferase gene of pGL3-enhancer with enhanced green
fluorescence protein (EGFP) as follows: EGFP coding
region were amplified by PCR using primers 5'-GACTTTC-
CAAAATGTCGTAACAACTCC-3' (forward) and 5'-
GGCTCTAGATTACTTGTACAGCTCGTC-3' (reverse) with
pEGFP-C2 as template, cut with double restriction enzyme
NcoI and XbaI, then cloned into the vector fragment of
pGL3/Enhancer/-404,+46 or pGL3/Enhancer/-266,-212
which were cut with the same restriction enzymes NcoI
and XbaI to release the luciferase coding region.
Construction of pCMV-HA/c-Myc, pCMV-HA/Sp1 and 
pRNA-U6.1/neo/Sic-Myc
The coding region of c-Myc and Sp1 were amplified by
PCR using primers list in Table 2 with fetal brain cDNA
library as templates, digested with enzyme EcoRI/XholI,
then subcloned into pCMV-HA vectors cut with two corre-
sponding enzymes, and named as pCMV-HA/c-Myc and
pCMV-HA/Sp1.
Table 1: Primers used to construct reporter vectors originating from the construct pGL3-404/+46.
pGL3-404/+46/(del-293/-168) Forward: 5'-GTCTTCTCGAGAGGGGCAT-3'
Reverse: 5'-ACCGGAGGTGGTGCT-3
pGL3-404/+46/(del-152/+3) Forward: 5'-GGCAAGAAGCACAAGAA-3'
Reverse: 5'-CCCCTCTCGAGAAGAC-3'
pGL3-311/+46 Forward: 5'-TGCAGCACCACCTCC-3'
Reverse: 5'-GTACCTATCGATAGAGAAATGTTC-3'
pGL3-266/+46 Forward: 5'-GGCACCCTGTGCGCGCGGCGGGCCTTCT-3'
Reverse: 5'-CGTAGAGGTGTTTGTCCGACTTGTGC-3'
pGL3-168/+46 Forward: 5'-GTCTTCTCGAGAGGGGCAT-3'
Reverse: 5'-GTACCTATCGATAGAGAAATGTTC-3'BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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To generate c-Myc knockdown vector, two annealed sets of oli-
gonucleotides encoding short hairpin transcripts corresponding
to nt 1357–1377 (insert 1) and nt 1716–1738 (insert 2) of c-myc
mRNA (GenBank accession no. NM-002467) (21) were cloned
into pRNAT-U6.1 vector (GenScript Corp.). The oligonucle-
otides encoding short hairpin transcripts to silence the expres-
sion of c-Myc were insert 1 (sense 5'-
GATCCCGTTGGACAGTGTCAGAGTCTTCAAGAGAGACTCTGA
CACTGTCCAACTTTTTTCCAAA-3' and antisense 5'-
AGCTTTTGGAAAAAAGTTGGACAGTGTCAGAGTCTCTCTTGAA
GACTCTGACACTGTCCAACGG-3')  and insert 2 (sense 5'-
GATCCCGCATTTCTGTTAGAAGGAATCGTTCAAGAGACGATT
CCTTCTAACAGAAATGTTTTTTCCAAA-3' and antisense 5'-
AGCTTTTGGAAAAAACATTTCTGTTAGAAGGAATCGTCTCTTG
AACGATTCCTTCTAACAGAAATGCGG-3'). pRNA-U6.1/Neo
empty vectors were used as control. All the DNA inserts were
synthesized in TaKaRa cooperation, Dalian, China, subcloned
into the pRNA-U6.1/Neo vector (GenScript, USA) cut with
BamH I and Hind III, then transformed into competent JM109
cells. Positive clones were sequenced to verify the correct inserts,
then named as pRNA-U6.1/neo/Sic-Myc.
Establishing of clone pools that stably expresses SiRNA 
against c-Myc expression
24 h prior transfection, 1 × 106 5-8F cells were seeded in
6-well plate, then transfected with 1 μg of pRNA-U6.1/
neo/c-Myc and control vector pRNA-U6.1/neo by Lipo-
fectamine 2000 Reagent (Invitrogen) according to manu-
facturer's instructions. 72 h after transfection, the cells
were grown in 1640 medium containing 10% fetal bovine
serum and 350 μg/ml G418 for 2 weeks to screen positive
clone pools, and named as 5-8F/Si-c-Myc and 5-8F/Si-
control.
Luciferase assay
4 × 105 cells were seeded in each well of 12-well plates 24
h prior transfection, then transfected with 0.5 μg of vari-
ous BRD7 promoter constructs and 0.25 μg SV40 β-galac-
tosidase vector per well for normalizing transfection
efficiency by Lipofectamine 2000 Reagent (Invitrogen)
according to manufacturer's instructions. To detect the
effects of transcriptional factor Sp1 and c-Myc on the pro-
moter activity of BRD7 gene, cultured cells were trans-
fected with 0.5 μg BRD7 promoter constructs, 0.25 μg
SV40 β-galactosidase vector and various amount pCMV-
HA/Sp1 and pCMV-HA/c-Myc, respectively. Firefly luci-
ferase activity was measured in cell lysates 38 h after trans-
fection by using Luciferase Assay kit (Promega). β-
galactosidase activity was measured in cell lysates by β-
galactosidase Enzyme Assay System (Promega). Experi-
ments were repeated at least three times with three repli-
cates per sample for each experiment. Results are
normalized against β-galactosidase activity.
Detection of direct GFP fluorescence
Cells were seeded in 12-well plates to 70–80 confluent on
the day of transfection, then transfected with 0.5 μg of
promoter reporter constructs pGL3/-404,+46/EGFP or
pGL3/-266,-212/EGFP per well by Lipofectamine 2000
Reagent. To detect the effects of transcriptional factors c-
Myc on the promoter activity of BRD7 gene, cultured cells
were transfected with 0.5 μg BRD7 promoter constructs
which expressed EGFP and various amounts of pCMV-
HA/c-Myc. pCMV-HA was used as control. The signal of
EGFP fluorescence was observed 38 h after transfection by
an AX-80 analytical microscope system (Olympus, Tokyo,
Japan).
Immunoblot assay
Cultured Cells were harvested with a lysis buffer consist-
ing of 50 mM Tris-HCl (pH7.5), 0.1% sodium dodecyl
sulfate (SDS), 1% Triton X-100, 150 mM NaCl, 1 mM
dithiothreitol, 0.5 mM EDTA, 0.1 mM phenylmethylsul-
fonyl fluoride, 12 mg/ml leupeptin, 20 mg/ml aprotinin,
100 mM sodium vanadate, 100 mM sodium pyrophos-
phate and 1 mM sodium fluoride. The concentrations of
the protein extraction were determined by using Bradford
assay (Bio-Rad, Hercules, CA) with bovine serum albumin
as a standard. Equal amounts of total protein were loaded
in each lane of an SDS-PAGE gel (12% acrylamide). After
completion of gel electrophoresis, protein was transferred
to nitrocellulose membrane (PALL) for 1.5 h using a blot-
ting apparatus. The immunoblots were incubated sequen-
tially with primary antibodies and horseradish
peroxidase-coupled secondary antibodies. Signals were
generated by chemiluminescence with ECL substrate rea-
gent (Pierce).
Electrophoretic mobility shift assay (EMSA)
Nuclear protein was prepared by using NR-PER Nuclear
and Cytoplasmic Extraction Reagents (Pierce Biotechnol-
ogy) according to the instructions of the manufacturer.
EMSAs were performed according to the gel shift assay sys-
tem (Promega) with minor modifications. Complemen-
Table 2: Primers used to amplify the coding region of c-Myc and Sp1 gene.
pCMV-HA/c-Myc Forward: 5'-ACAGAATTCACATGCCCCTCAACGTTAGCTTCAC-3'
Reverse: 5'-TTTCTCGAGTCCTTACGCACAAGAGTTCCGTAGCTG-3'
pCMV-HA/Sp1 Forward: 5'-TTTGAATTCCTGCCACCATGAGCGACCAAGAT-3'
Reverse: 5'-CACCTCGAGGCCTGATCTCAGAAGCCATT-3'BMC Molecular Biology 2008, 9:111 http://www.biomedcentral.com/1471-2199/9/111
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tary oligonucleotides including oligos spanning the
potential binding sites of transcription factor Myc-MAX,
E2F6 and Sp1 in BRD7 promoter region were synthesized
in TaKaRa Biotechnology Company. Eight micrograms of
each complementary oligo was boiled for 10 min, cooled
for 3 h at room temperature, and left overnight at 4°C.
Probes were radiolabeled with [γ-32P]ATP (30–50 μCi,
3000 Ci/mmol) by 10 U T4 Polynucleotide kinase and
purified on a G25 Sephadex column. Nuclear protein (8
μg in final reaction volumes of 10 μl) from 5-8F cells was
incubated for 20 min at room temperature in the presence
or absence of a 100-fold molar excess (relative to the radi-
oactive substrate) of wild type or mutated oligonucleotide
duplex competitors. Then 20–30,000 cpm of labeled
probe oligonucleotide duplexes was added to the reac-
tion. After another 20 min of incubation at room temper-
ature, the samples were analyzed by electrophoresis
through a 6% polyacrylamide gel run in 0.5 × Tris-borate-
EDTA for 40 min at 300V, followed by detection of the
radioactive species by autoradiography. In the supershift
experiments, 2 μg antibody of Sp1 (Upstate Biotechnol-
ogy), c-Myc (Sigma), E2F6 (Santa Cruz Biotechnology)
and irrelevant anti-HA (Santa Cruz Biotechnology) was
added to the reaction, respectively.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using a kit from Upstate Bio-
technology according to the recommendations of the
manufacturer. After the steps of ChIP assay, the immuno-
complexes were eluted by incubation for 15 min at 25°C
with 200 μl of elution buffer (1% SDS, 100 mM NaHCO3,
1 mM DTT), and reversed at 65°C for 4 h. DNA fragments
were extracted with phenol/chloroform and precipitated
with ethanol. A fragment of the BRD7 promoter was
amplified by semi-quantitative PCR with primers as fol-
lows: 5'-AGCCGCCGGCACCCTGTG-3' (forward) and 5'-
GAGAAGACGGCGCGCGAGA-3' (reverse). An unrelated
genomic region of GAPDH gene used as negative control
was amplified by PCR with the primers as follows: 5'-
CGACCACTTTGTCAAGCTCA-3' (forward) and 5'-
AGGGGTCTACATGGCAACTG-3' (reverse), yielding a
228-bp product. PCR was carried out for 35 cycles by
using a step cycle of 94°C for 30 s, 54°C for 50 s, 72°C for
1 min, followed by 72°C for 10 min. The PCR products
were analyzed by electrophoresis on a 2% ethidium bro-
mide-stained agarose gel.
RT-PCR and real-time PCR
RT-PCR was performed as previously described (14). The
single-stranded cDNA was amplified by using primers as
follows: BRD7 primer (forward) 5'-CAAGCTCTT-
TAGCCAAACAAGAA-3', (reverse) 5'-TCATTCCTGAGT-
GCAACAGC-3'; c-Myc primer (forward) 5'-
AGCGACTCTGAGGAGGAACA-3', (Reverse) 5'-
TCGCCTCTTGACATTCTCCT-3'; GAPDH primer (for-
ward) 5'-TCTAGACGGCAGGTCAGGTCCACC-3',
(Reverse) 5'-CCACCCATGGCAAATTCCATGGCA-3'. PCR
was carried out for 28 cycles using a step cycle of 94°C for
40 s, 58°C for 40 s, 72°C for 1 min, followed by 72°C for
10 min. GAPDH primer was added to the reactions at the
end of the fifth cycle. Quantitative real-time PCR was per-
formed with an ABI PRISM 7700 thermal cycler (Applied
Biosystem) using SYBR® Premix Ex Taq™ (TaKaRa, Dalian,
China.) by using the primers as in the experiment of RT-
PCR. The thermal cycling conditions were were a 10
minute hold at 95°C followed by 45 cycles of 95°C for 15
seconds, 55°C for 30 seconds and 72°C 30 seconds. Cal-
culations were performed according to the cycle threshold
method. The PCR results were normalized to human glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH)
expression. Results (mean ± S.E.) were expressed as fold
relative to the expression of GAPDH, which was set to 1.
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